A phase i clinical trial of weekly oral topotecan for relapsed small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 45-51

  Agelaki, S ^a,b   Kontopodis, E ^a   Kotsakis, A ^a,b   Chandrinos, V ^c   Bompolaki, I ^d   Zafeiriou, Z ^a   Papadimitraki, E ^a   Stoltidis, D ^a   Kalbakis, K ^a   Georgoulias, V ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d Chania General Hospital St George   (Greece)

Author keywords

Oral topotecan; Phase I; SCLC; Weekly schedule

Indexed keywords

TOPOTECAN;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PALLIATIVE CARE; SMALL CELL LUNG CARCINOMA; THROMBOCYTOPENIA; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84879796271     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2167-0     Document Type: Article

References (27)

1. Hurwitz JL, McCoy F, Scullin P, Fennell DA (2009) New advances in the second-line treatment of small cell lung cancer. Oncologist 14(10):986-994
2. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25(15):2086-2092
3. Kim YH, Mishima M (2011) Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 37(2):143-150
4. Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20(1):73-96
5. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658-667
6. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24(34):5441-5447
7. Treat J (2003) Weekly topotecan in the management of lung cancer. Lung Cancer 41(Suppl 4):S27-S31
8. Bence AK, Mattingly CA, Desimone PA, Doukas MA, Adams VR (2002) Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells. Proc Am Assoc Cancer Res 43:247
9. Eckardt JR (2004) Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 9(Suppl 6):25-32
10. McCabe FL, Johnson RK (1994) Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 12(3):308-313
11. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101(10):708-720
12. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730-751
13. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, DHHS; 2006
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
15. Cox DR (1970) The analysis of binary data, 1st edn. Methuen, London
16. Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S et al (1998) Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 34(7):1030-1035
17. Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I et al (1998) Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 4(5):1153-1158
18. Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C et al (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15(3):1087-1093
19. Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I et al (1999) A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5(1):69-75
20. Stathopoulos GP, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, Athanasiadis A, Trafalis D, Anagnostopoulos A, Koutantos J et al (2010) Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anticancer Drugs 21(2):202-205
21. Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, Schellens JH (1999) Oral topotecan: bioavailability and effect of food co-administration. Br J Cancer 80(9):1380-1386
22. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG (2001) A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83(2):394-399
23. Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW (2010) A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. J Clin Pharmacol 50(3):268-275
24. Shah C, Ready N, Perry M, Kirshner J, Gajra A, Neuman N, Garziano S (2007) A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57(1):84-88
25. Spigel DR, Greco FA, Burris HA 3rd, Shipley DL, Clark BL, Whorf RC, Arrowsmith ER, Hainsworth JD (2011) A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clin Lung Cancer 12(3):187-191
26. Shipley DL, Hainsworth JD, Spigel DR, Gray JR, Barton JH, Switzer A, Nicolau M, Marsland T, Joseph G, Greco FA (2006) Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)-A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 24(18S):abstr. 7083
27. Gralla RJ (2004) Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 9(Suppl 6):14-24